#evaluate(de(' #AdditionalMetaTags# '))#
MOMM Diagnostics develops rapid, cost-effective diagnostic tests for pregnancy complications. préXclude® is our first test in development to diagnose and prognose preeclampsia a leading cause of death in pregnancy. Our innovative electrochemical lateral flow immunoassay enables early detection using a simple fingerstick blood sample, providing fast and reliable results at the point of care. By improving early diagnosis, we help reduce maternal and fetal risks, supporting better healthcare outcomes. Our primary customers include hospitals, clinics, and OB-GYNs, with a global maternal health market offering strong growth potential. MOMM aims to revolutionize prenatal care with accessible, high-performance diagnostics, addressing an urgent need for timely and affordable testing solutions.
Healthtech startups in the global spotlight (startupticker.ch)
Seven startups selected for the Swiss-Israel Lean Launchpad (startupticker.ch)
Access to global accelerators for three MedTech start-ups (startupticker.ch)
Four startups to explore South Africa’s health challenges (startupticker.ch)
Strong Swiss delegation at Medica Startup Park (startupticker.ch)
New bearers of the Innosuisse Certificate ready for the next level (startupticker.ch)
"You cannot do it alone" — Interview with Christian Elias Schneider of the Innovation Office at the University of Basel (venturelab.swiss)
Venture Leaders Medtech 2022: Captain’s blog by Oncobit CEO Claudia Scheckel (venturelab.swiss)
Venture Leaders Medtech: 10 Swiss medtech startups showcase cutting-edge innovations in Boston (venturelab.swiss)
MOMM Diagnostics: The Venture Leader Medtech developing high-sensitivity rapid diagnostic tests (venturelab.swiss)
The road to Boston: The Venture Leaders Medtech 2022 kick-off their international roadshow (venturelab.swiss)
Venture Leaders Medtech 2022: 10 innovative startups will advance their global growth in Boston (venturelab.swiss)
préXclude Alpha Prototype